Neldazosin is a pharmaceutical compound primarily classified as an alpha-1 adrenergic antagonist, which is used in the treatment of hypertension and benign prostatic hyperplasia (BPH). Its mechanism of action involves blocking alpha-1 adrenergic receptors, leading to vasodilation and a subsequent decrease in blood pressure. Neldazosin is characterized by its ability to selectively inhibit these receptors, which helps alleviate urinary symptoms associated with BPH by relaxing smooth muscle in the prostate and bladder neck. The compound is typically administered orally and is known for its relatively favorable side effect profile compared to other medications in its class. In terms of chemical properties, Neldazosin has a specific molecular structure that contributes to its pharmacological activity, and it is often studied for its potential interactions with other medications. As with any pharmaceutical agent, it is essential to consider its pharmacokinetics, including absorption, distribution, metabolism, and excretion, to understand its efficacy and safety in clinical use.

Neldazosin

109713-79-3: 1-(4-Amino-6,7-dimethoxy-2-quinazolinyl)-4-(3-hydroxy-1-oxobutyl)piperazine, 1-(4-Amino-6,7-dimethoxy-2-quinazolinyl)-4-(3-hydroxybutyryl)piperazine, 1-Butanone, 1-[4-(4-amino-6,7-dimethoxy-2-quinazolinyl)-1-piperazinyl]-3-hydroxy-, 1-[4-(4-Amino-6,7-Dimethoxyquinazolin-2-Yl)Piperazin-1-Yl]-3-Hydroxybutan-1-One, 1-[4-(4-Amino-6,7-dimethoxy-2-quinazolinyl)-1-piperazinyl]-3-hydroxy-1-butanone, Hro 2/145, Neldazosin [INN], Neldazosina, Neldazosina [INN-Spanish], Neldazosine, Neldazosine [INN-French], Neldazosinum, Neldazosinum [INN-Latin], Piperazine, 1-(4-amino-6,7-dimethoxy-2-quinazolinyl)-4-(3-hydroxy-1-oxobutyl)-, Unii-G3E7Ro42Mb, Neldazosin

CAS 109713-79-3: Neldazosin

Neldazosin

Ref: TM-T61535

Neldazosin

Ref: 54-BUP08715